Shares of Align Technology, Inc. (NASDAQ:ALGN – Get Free Report) have been given a consensus rating of “Moderate Buy” by the sixteen brokerages that are covering the company, Marketbeat reports. Seven investment analysts have rated the stock with a hold recommendation, eight have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average twelve-month target price among analysts that have issued ratings on the stock in the last year is $201.71.
A number of brokerages have recently issued reports on ALGN. Needham & Company LLC reissued a “hold” rating on shares of Align Technology in a research report on Thursday, July 30th. UBS Group reaffirmed a “neutral” rating and issued a $189.00 target price on shares of Align Technology in a report on Thursday, July 23rd. BMO Capital Markets assumed coverage on Align Technology in a research report on Wednesday, July 8th. They set an “outperform” rating and a $209.00 target price on the stock. Zacks Research lowered Align Technology from a “strong-buy” rating to a “hold” rating in a report on Thursday, July 16th. Finally, Evercore cut Align Technology from an “outperform” rating to an “in-line” rating and set a $155.00 price target for the company. in a research report on Monday.
Get Our Latest Stock Report on ALGN
Align Technology Stock Performance
Align Technology (NASDAQ:ALGN – Get Free Report) last announced its earnings results on Wednesday, July 29th. The medical equipment provider reported $2.64 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.62 by $0.02. Align Technology had a return on equity of 15.86% and a net margin of 9.99%.The business had revenue of $1.06 billion for the quarter, compared to analysts’ expectations of $1.05 billion. During the same period last year, the firm posted $2.49 earnings per share. The business’s revenue for the quarter was up 4.3% on a year-over-year basis. Equities analysts predict that Align Technology will post 9.38 earnings per share for the current year.
Institutional Inflows and Outflows
Hedge funds have recently made changes to their positions in the stock. Blue Trust Inc. raised its holdings in Align Technology by 77.5% during the first quarter. Blue Trust Inc. now owns 158 shares of the medical equipment provider’s stock valued at $27,000 after acquiring an additional 69 shares during the period. Tobam purchased a new position in shares of Align Technology in the fourth quarter valued at about $30,000. Hollencrest Capital Management bought a new position in shares of Align Technology in the first quarter worth about $34,000. Osterweis Capital Management Inc. bought a new position in shares of Align Technology in the second quarter worth about $36,000. Finally, Global Retirement Partners LLC purchased a new stake in shares of Align Technology during the second quarter worth about $38,000. 88.43% of the stock is currently owned by institutional investors.
Align Technology Company Profile
Align Technology, Inc is a medical device and digital technology company that designs, manufactures and markets products used in orthodontics and restorative dentistry. The company is best known for Invisalign clear aligners, which are custom-made orthodontic devices intended to gradually move patients’ teeth under the supervision of dental professionals.
Align also develops the iTero family of intraoral scanners and related digital imaging systems, which help dental professionals create digital impressions and treatment plans.
Read More
- Five stocks we like better than Align Technology
- Want Private-Market Access to Kalshi and Polymarket? Try This ETF
- Levi’s Stock Dip Reveals Value Opportunity Despite Q3 Headwinds
- PepsiCo Stock Looks Poised to Bottom With High Yield, Deep Value
- Alphabet’s $1.8 Billion Black Hills Deal Powers AI Data Center Push
Receive News & Ratings for Align Technology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Align Technology and related companies with MarketBeat.com's FREE daily email newsletter.
